Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2016 by Sidney Kimmel Comprehensive Cancer Center
Sponsor:
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT01665768
First received: July 27, 2012
Last updated: May 17, 2016
Last verified: May 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: July 2018
  Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)